Navigation Links
Anti-clotting drugs yield similar results
Date:8/26/2012

DURHAM, N.C. The first trial to study patients with acute coronary syndrome who do not undergo coronary stenting or bypass surgery found no significant difference between two anti-clotting drugs prasugrel and clopidogrel in preventing the first occurrence of death, heart attack or stroke, according to Duke University Medical Center cardiologists.

The study also showed no difference in serious bleeding complications.

At the same time, the Duke researchers observed an unexpected reduction in heart attack, stroke and death among patients treated with prasurgrel beyond one year of treatment. The researchers say this potential time-dependent benefit requires further exploration.

The results were presented by the Duke researchers at the European Society of Cardiology Scientific Sessions in Munich, Germany today, and published online in the New England Journal of Medicine.

"If you look at this study as a comparison of two drugs, it doesn't tell the whole story," says E. Magnus Ohman, M.D., a professor of medicine at Duke and chairman of the TRILOGY ACS study. "This is a unique patient population that has never before been studied."

Acute coronary syndrome (ACS) refer to a group of conditions that include heart attacks and chest pain caused by clogged coronary arteries. To date, most trials evaluating anti-clotting drugs for ACS patients have focused on patients who undergo revascularization procedures such as stent implantation with percutaneous coronary intervention and coronary artery bypass surgery to restore blood flow.

Up to 60 percent of ACS patients worldwide undergo revascularization procedures according to published data. The remaining 40 percent are managed solely with drug therapy. These patients are at higher risk for repeated cardiovascular-related events, such as heart attack, stroke, and death.

"Optimizing medical therapy for these patients is extremely important," Ohman says.

Prasugrel and clopidogrel are members of the thienopyridine class of adenosine diphosphate receptor inhibitors that prevent the formation of blood clots in arteries by binding to specific receptors and inhibiting the clumping of platelets.

The efficacy and safety of the two drugs were first compared in a Phase III trial called TRITON that evaluated 13,608 ACS patients who planned to undergo stent implantation. The TRITON study, published in 2007, found that 10 mg of prasugrel was 19 percent more effective in preventing cardiovascular death, nonfatal heart attacks and strokes than clopidogrel. It also found prasurgrel caused a higher incidence of fatal bleeding.

TRILOGY ACS is a Phase III, double-blind, randomized trial that was developed as a follow-up to the TRITON trial.

"We designed our study to see if prasugrel was just as effective in patients who aren't getting coronary stents or coronary bypass surgery," says Ohman.

TRILOGY ACS enrolled 9,326 participants at 966 sites in 52 countries. It compared up to 2.5 years of treatment with prasugrel 10 mg daily vs. clopidogrel 75 mg daily, both in combination with aspirin, in ACS patients who were younger than age 75 years. The prasugrel dose was reduced to 5 mg daily for patients weighing less than 60 kilograms. A secondary analysis also looked at patients who were age 75 years or older who received 5 mg of prasurgrel daily vs. clopidogrel 75 mg daily because TRITON demonstrated an increased risk of major bleeding in these patients when they were treated with prasugrel 10mg daily.

After a median of 17 months of follow up, the primary end point - described as the time to first occurrence of death, heart attack or stoke - occurred in 13.9 percent of patients under age 75 years vs. 16.0 percent of those treated with clopidogrel. This is considered a non-significant difference.

However, a lower risk of recurrent adverse events with prasugrel was observed after 12 months of treatment. "This finding has not been observed in previous studies such as TRITON that evaluated a shorter duration of treatment," said Dr. Ohman. "We believe further exploration of this finding is needed."

The researchers did not observe an increase in severe or life-threatening bleeding complications with prasugrel as seen in the TRITON study. "Because we modified the prasugrel dose for patients with a higher risk of bleeding, we observed that prasugrel is as safe as clopidogrel with long-term treatment," said Dr. Ohman.


'/>"/>
Contact: Debbe Geiger
Debbe.Geiger@duke.edu
919-660-9461
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. Pharmacy Robots Linked to Bacterial Contamination of Drugs
2. Penn study cautions use of drugs to block niacin flush
3. Urinary Incontinence Drugs May Be More Trouble Than Theyre Worth
4. Discovery could help to develop drugs for organ transplant and cancer patients
5. Not taking gastroprotective drugs prescribed with anti-inflammatory medicines
6. Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment
7. Weight-Loss Surgery Beat Drugs for Cutting Diabetes in Very Obese
8. Seniors Stop Taking Heart Drugs In Medicare Donut Hole
9. New Psoriasis Drugs Not Much Better Than Standard Therapy, Study Finds
10. About 1 baby born each hour addicted to opiate drugs in U.S., U-M study shows
11. Blood pressure drugs linked with lower PTSD symptoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh has ... the world. Yisrayl says this generation is a time like no other and society needs ... Bible. , Yisrayl says he does not want to sound like an old bible beater ...
(Date:1/20/2017)... ... January 20, 2017 , ... ATP Science, an Australian-based company ... attended the January ECRM Trade Show in Hilton Head, SC, benefiting from outstanding ... range of supplements that keep the body functioning at its peak performance by ...
(Date:1/20/2017)... ... ... Magdalene: Grace is Greater than Sin”: a unique and memorable piece of literature ... Grace is Greater than Sin” is the creation of published author, Brenda Roberts, a ... had little knowledge of the female characters portrayed in the Holy Bible. , ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Christmas in Suffolk”: a story ... Sara Seymour, who lives in Lafayette, Indiana where she works in a daycare and ... and writes. , Published by Christian Faith Publishing, Sara Seymour’s new book is an ...
(Date:1/19/2017)... ... ... the Centers for Medicare & Medicaid Services (CMS) announced over 359,000 clinicians are ... who participate in APMs are paid for the quality of care they give to ... a system that delivers better care and one in which clinicians work together to ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 Conference Call and Webcast to ... ) today announced it will release results for the fourth quarter ... ... host a conference call at 4:30 PM ET on Wednesday, February ... full year 2016 financial results and other corporate activities. To participate ...
(Date:1/19/2017)... , Jan. 19, 2017  Stealth BioTherapeutics Inc. ( ... treat mitochondrial dysfunction, today announced new additions to its ... as Chief Medical Officer, and Daniel Geffken ... that Jim Carr , Pharm.D. has been promoted ... are pleased to welcome Doug and Daniel to our ...
(Date:1/19/2017)... 19, 2017  Abaxis, Inc. (NasdaqGS: ABAX ... instruments and consumables for the medical and veterinary markets ... financial results for the third quarter fiscal year 2017, ... 4:15 p.m. ET on Thursday, January 26, 2017.  The ... fiscal year 2017 after the market closes on Thursday, ...
Breaking Medicine Technology: